NICHIBAN (4218) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 of the fiscal year ending March 2026, Nichiban recorded higher revenue but lower earnings, with the key characteristic being the inability to convert revenue growth into profit growth. Revenue increased modestly to ¥377.5B (+1.0% YoY), while Operating Income declined by double digits to ¥17.6B (-25.1%), Ordinary Income to ¥19.0B (-21.8%), and Net Income to ¥12.7B (-24.2%). The Operating Income margin declined to 4.7% from 6.3% in the same period of the previous year, primarily due to deteriorating profitability in the core Medical Business and an increase in corporate expenses.

Factors Affecting Earnings

【Revenue】Revenue was ¥377.5B, an increase of +1.0% YoY. By segment, the Tape Business generated ¥189.8B (+1.8%), while the Medical Business generated ¥188.9B (+0.1%). Within the Tape Business, the Industrial Products Field (¥103.7B, +3.9%) and Overseas Global Field (¥38.1B, +3.2%) drove growth. Meanwhile, the Domestic Consumer Sales Headquarters (¥116.4B, -0.9%) recorded lower revenue, indicating a lack of strength in domestic consumer-related demand.

【Profit and Loss】Operating Income was ¥17.6B, a decline of -25.1% YoY. Segment Income declined in both the Medical Business, at ¥48.1B (-7.4%, margin of 25.5%), and the Tape Business, at ¥6.0B (-2.8%, margin of 3.1%). In addition, unallocated corporate expenses increased by +5.4% YoY to ¥35.2B, further expanding the decline in consolidated Operating Income. Net non-operating income and expenses resulted in a gain of ¥1.4B, lifting Ordinary Income to ¥19.0B, but this was insufficient to offset the decline in Operating Income. As a result of recording ¥0.8B in extraordinary losses, including losses on the disposal of fixed assets, Profit Before Tax was ¥18.2B. Overall, the period can be characterized as one of higher revenue but lower earnings.

Segment Analysis

The Medical Business generated revenue of ¥188.9B (+0.1% YoY), which was essentially flat, while Segment Income declined to ¥48.1B (-7.4%), and the margin fell to 25.5% from 27.6% in the previous year. Although it is the largest contributor to profit, deteriorating profitability in this segment is weighing on consolidated performance. The Tape Business recorded higher revenue of ¥189.8B (+1.8%), led primarily by the Industrial Products Field, but Segment Income remained at ¥6.0B (-2.8%), and the margin edged down to 3.1% from 3.3% in the previous year. Revenue growth has not translated into profit growth, suggesting weak cost absorption capacity. Combined Segment Income from the two businesses was ¥54.1B (¥57.1B in the previous year, -5.3%). After deducting corporate expenses of ¥35.2B (+5.4% YoY), consolidated Operating Income was ¥17.6B.

Key Financial Indicators

【Profitability】The Operating Income margin was 4.7%, down approximately 1.6pt from 6.3% in the same period of the previous year, while the Net Income margin also contracted to 3.4% from 4.5%. The gross margin was 29.9% and the SG&A expense ratio was 25.3%, indicating negative operating leverage as the Company was unable to fully absorb the additional revenue.【Cash Quality】Period-end Net Income was ¥12.7B, while comprehensive income was ¥12.9B, representing close to an exact match. An increase of ¥1.3B in valuation difference on other securities and a decline of ¥0.9B in retirement benefit adjustments largely offset each other, with no significant divergence in earnings quality.【Investment Efficiency】ROE was 2.9%, with capital returns constrained alongside the decline in the Operating Income margin. Total assets were ¥680.9B, and asset turnover efficiency was moderate relative to revenue during the period.【Financial Soundness】The Equity Ratio remained high at 64.3% (approximately 64.0% in the previous year), while current assets of ¥403.6B substantially exceeded current liabilities of ¥185.6B. The financial base is conservative, and there is limited need to view declining profitability as a financial risk.

Cash Flow Analysis

As the Company does not disclose a cash flow statement, funding trends are reviewed based on changes in the balance sheet. Cash and deposits were ¥131.6B, a decrease of ¥15.0B from ¥146.6B at the end of the previous year. Meanwhile, accounts receivable and notes receivable increased to ¥102.2B from ¥89.6B in the previous year, and inventories also edged up to ¥56.8B from ¥56.3B, suggesting that an expansion in working capital may have contributed to the decline in cash. Retained earnings continued to increase to ¥330.3B from ¥324.8B in the previous year, indicating that the current-period profit has been retained internally. If reductions in trade receivables and inventories progress, there appears to be considerable room for improvement in cash efficiency going forward.

Earnings Quality

The primary differences between Ordinary Income of ¥19.0B and Net Income of ¥12.7B were extraordinary losses of ¥0.8B, including ¥0.4B in losses on the disposal of fixed assets, and ¥5.5B in income taxes and other taxes. Both are ordinary expense items, and there were no temporary factors that boosted earnings. Non-operating income of ¥2.9B included dividend income of ¥0.3B, foreign exchange gains of ¥0.3B, and other non-operating income of ¥1.1B. Non-operating expenses of ¥1.5B included interest expense of ¥0.3B. Financial income and expenses were broadly balanced, with no significant premium or discount to recurring earnings power. Comprehensive income of ¥12.9B was broadly in line with Net Income of ¥12.7B. Given that the increase in valuation differences on other securities and the decrease in adjustments related to retirement benefits offset each other, earnings distortion attributable to accrual factors appears limited.

Earnings Forecast and Guidance

The full-year Company forecast is Revenue of ¥500.0B (+1.1% YoY), Operating Income of ¥22.0B (-15.0%), Ordinary Income of ¥23.0B (-14.2%), and Net Income of ¥14.0B. The cumulative Q3 progress rates were 75.5% for Revenue, 80.0% for Operating Income, 82.6% for Ordinary Income, and 90.4% for Net Income, all exceeding the standard 75% progress benchmark. However, the full-year forecast Operating Income margin of 4.4% is below the 4.7% recorded for the cumulative period, indicating that the Company anticipates profitability to remain more cautious through Q4. While revenue progress is proceeding smoothly and profit progress appears ahead of schedule, maintaining or improving profitability is a prerequisite for achieving the full-year forecasts.

Shareholder Returns

The full-year dividend forecast is ¥40.00 per share. As the Q2 dividend was ¥0, the dividend is concentrated in the year-end payment. The Payout Ratio against the full-year forecast EPS of ¥68.77 is approximately 58.2%. Although this is below the sustainability guideline of 60%, the headroom is limited. Retained earnings are substantial at ¥330.3B, and sufficient dividend resources are secured on the balance sheet. Future dividend sustainability is expected to depend not only on achievement of the full-year earnings plan but also on improvements in cash efficiency through working capital reduction.

Risk Factors

1. Deteriorating profitability in the core business: While revenue in the Medical Business was essentially flat at +0.1% YoY, Segment Income declined by -7.4%, and the margin fell to 25.5%. If the recovery in profitability of the business generating more than half of consolidated profit is delayed, the impact on full-year performance may continue.

2. Working capital tied up: Accounts receivable and notes receivable were ¥102.2B, and inventories were ¥56.8B; both increased from the previous year. The collection of receivables and inventory-level management may affect cash efficiency. In particular, product inventories of ¥56.8B account for the majority of inventories.

3. Pressure on profitability from higher corporate expenses: Unallocated corporate expenses increased to ¥35.2B (+5.4% YoY), weighing on consolidated Operating Income in combination with the decline in combined Segment Income from the two businesses. Control of fixed costs will influence future trends in profit margins.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The Company's profitability is below the industry median, and its Operating Income margin is positioned at the lower-IQR level of the industry.

Growth and Capital Efficiency

Revenue growth is also below the industry median, but remains above the negative lower bound of the industry IQR and is not extremely low.

※Source: Compiled by the Company

Key Points from the Financial Results

1. Progress against the full-year forecast was 80.0% for Operating Income and 90.4% for Net Income, appearing ahead of schedule numerically. However, this reflects the high performance level in the same period of the previous year, and the underlying structure of higher revenue but lower earnings—Revenue growth of +1.0% versus a -25.1% decline in Operating Income—has not improved.

2. There is a significant profitability gap between the core Medical Business (25.5% margin) and the Tape Business (3.1% margin). For a sustained improvement in the consolidated profit margin, the Company must simultaneously restore profitability in the Medical Business and improve margins in the Tape Business.

3. Financial soundness is favorable, with an Equity Ratio of 64.3% and a current ratio exceeding 200%; declining profitability is not directly translating into financial risk. The financial results indicate that the cost structure and working capital trends related to restoring profitability should be key areas for monitoring going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,744–¥1,842 at cost of equity ±1%, and ¥1,781–¥1,799 at ω±0.1.

Notes:

• Because Net Income progress against the full-year forecast (90%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies ahead of schedule tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets at the end of the quarter are used (there is a timing difference relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat on the high side.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was weak, with modest sales growth failing to offset a marked deterioration in profitability. Revenue increased 1.0% YoY to ¥37.75bn. Operating income declined 25.1% YoY to ¥1.76bn, while ordinary income fell 21.8% to ¥1.90bn. Net income attributable to owners decreased 24.2% to ¥1.27bn. Gross profit fell 1.7% YoY to ¥11.30bn despite the higher revenue base. The gross margin compressed by 88bp YoY to 29.9%. SG&A expenses increased 4.0% YoY to ¥9.54bn, raising the SG&A-to-sales ratio by 74bp to 25.3%. Consequently, the operating margin contracted by 163bp to 4.7%, below the 5% low-efficiency threshold. Net margin fell by 112bp YoY to 3.4%. Medical remained the core business by segment-profit contribution, but its segment profit declined 7.4% YoY. Tape sales outperformed Medical on growth, but Tape segment profit also fell. Non-operating income of ¥0.29bn, including ¥0.03bn of FX gains, only partly softened the operating decline. Extraordinary losses of ¥0.08bn, including ¥0.04bn of fixed-asset disposal losses, further reduced earnings. The balance sheet remains sound, supported by a 217.5% current ratio, 64.3% equity ratio and 53.4x interest coverage. The full-year forecast implies Q3 progress of 75.5% for sales, 80.0% for operating income and 90.4% for net income, indicating that the company is broadly positioned to achieve its profit targets despite weak year-on-year earnings. The main forward-looking issue is whether the company can restore gross margin and contain overhead growth while reducing its elevated working-capital cycle.

Profitability Analysis

Reported annualized ROE was 3.9%, decomposed into a 3.4% net profit margin, 0.739x annualized asset turnover and 1.56x financial leverage. The principal driver of weak returns is profitability rather than leverage: the 3.4% net margin is low and the 4.7% EBIT/operating margin is below the 5% efficiency warning threshold. Asset turnover is moderate for a manufacturer, while leverage is conservative and does not represent an aggressive attempt to enhance shareholder returns. Gross margin declined from 30.8% to 29.9%, a deterioration of 88bp, indicating that cost of sales increased faster than revenue. SG&A increased 4.0% while revenue rose only 1.0%, creating negative operating leverage and reducing operating income by ¥0.59bn. Operating margin therefore compressed from 6.3% to 4.7%, or 163bp. The tax burden was 0.695, equivalent to a 30.4% effective tax rate, which was broadly normal but modestly below the 0.70 reference level. The interest burden was 1.034 because non-operating income exceeded interest expense, while interest expense of ¥0.03bn remained negligible relative to EBIT. Medical generated ¥4.81bn of segment profit, far exceeding Tape's ¥0.60bn and confirming Medical as the core business. Medical sales were broadly flat at ¥18.83bn, up 0.1% YoY, but segment profit declined 7.4% YoY, reducing its segment margin from 27.6% to 25.6%. Tape sales increased 1.6% to ¥18.93bn, but segment profit declined 2.8% to ¥0.60bn and its margin remained thin at 3.1%. Corporate and unallocated costs increased from ¥3.34bn to ¥3.52bn, further amplifying the gap between combined segment profit and consolidated operating income.

Growth Assessment

Top-line growth was limited to 1.0% YoY, with Tape contributing the relatively stronger 1.6% sales growth and Medical remaining essentially flat. Within domestic sales, industrial products in Tape rose 3.9% YoY to ¥10.37bn, while Medical healthcare-field sales declined 1.5% to ¥11.64bn. Overseas revenue increased 3.2% YoY to ¥3.81bn, supported by 10.7% growth in Medical global-field sales to ¥1.89bn; Tape global-field sales declined 3.2% to ¥1.92bn. Consumer-related domestic sales declined modestly, with the combined domestic consumer-sales subtotal falling to ¥19.14bn from ¥19.29bn. The combination of low sales growth and declining gross profit indicates that current growth is not translating into improved earnings quality. The full-year sales forecast is ¥50.00bn, and the Q3 cumulative achievement rate is 75.5%, close to the standard 75% seasonal benchmark. Operating income has achieved 80.0% of the ¥2.20bn full-year forecast, 5.0 percentage points ahead of the standard Q3 pace. Ordinary income has achieved 82.6% of forecast, 7.6 percentage points ahead of the standard pace. Net income has achieved 90.4% of forecast, 15.4 percentage points ahead of the standard pace, which indicates that the forecasted fourth-quarter net income requirement is modest at ¥0.13bn. However, achieving the operating-income forecast still requires ¥0.44bn in Q4 operating income, making margin discipline and demand stability important. The forecast itself calls for only 1.1% sales growth and a 15.0% operating-income decline for the full year, so management guidance does not yet imply a near-term return to the prior-year profitability level.

Financial Health

Liquidity is strong, with current assets of ¥40.36bn against current liabilities of ¥18.56bn, producing a current ratio of 217.5%. The quick ratio of 186.9% shows that liquidity remains ample even excluding inventories. Working capital was ¥21.80bn, supported by cash and deposits of ¥13.16bn. Total equity increased ¥0.58bn YoY to ¥43.77bn, and the equity ratio improved modestly to 64.3% from 63.9%. The debt-to-equity ratio of 0.56x is conservative and well below the 2.0x warning threshold. Interest coverage of 53.36x indicates very substantial capacity to service interest expense. Current liabilities increased ¥1.52bn YoY to ¥18.56bn, while non-current liabilities declined ¥1.61bn to ¥5.76bn. The increase in current liabilities includes ¥2.00bn of current portions of long-term loans, indicating a maturity reclassification that raises short-term obligations. Nevertheless, current assets exceed current liabilities by more than ¥21bn, substantially mitigating maturity-mismatch risk. Net defined-benefit liabilities increased 10.8% YoY to ¥1.96bn and remain a relevant long-term employee-benefit obligation. Asset retirement obligations total ¥0.78bn including current and non-current portions, equivalent to approximately 3.2% of total liabilities, an elevated but manageable environmental and restoration obligation for a manufacturing business.

Notable B/S Changes

Current liabilities: +¥1.52bn (+8.9%) to ¥18.56bn, including ¥2.00bn of current portions of long-term loans; this shifts debt maturity toward the short term, though strong current liquidity mitigates refinancing pressure. Non-current liabilities: -¥1.61bn (-21.9%) to ¥5.76bn, consistent with the movement of borrowing obligations into current liabilities and a shorter reported liability maturity profile. Asset retirement obligations: +¥0.18bn (+36.7%) in the non-current balance to ¥0.66bn; including ¥0.12bn current obligations, total ARO reached ¥0.78bn and should be monitored as an environmental/restoration liability. Trade receivables: +¥1.26bn (+14.0%) to ¥10.22bn, substantially faster than revenue growth and consistent with the elevated 74-day annualized DSO. Raw materials: +¥0.20bn (+11.3%) to ¥2.00bn, indicating a higher raw-material commitment that should be monitored alongside the elevated 101-day annualized inventory cycle.

Cash Flow Quality

The earnings profile warrants close monitoring through working-capital efficiency. Annualized receivable days were 74 days, above the 60-day warning level. The root cause is a high receivables base of ¥10.22bn, supplemented by ¥6.27bn of electronically recorded monetary claims. Relative to the prior-year receivables balance, trade receivables increased 14.0%, materially faster than 1.0% revenue growth. This can reflect customer mix, collection timing or extended credit terms; regardless of cause, it increases capital tied up in sales and reduces operating flexibility. Annualized inventory days were 101 days, above the 90-day warning threshold. Inventories increased 0.9% YoY to ¥5.68bn, while cost of sales increased 2.3%, suggesting the high inventory-day result is structural to the operating cycle rather than driven by a sharp year-on-year inventory build. Disclosed inventory components include raw materials of ¥2.00bn, work in process of ¥2.08bn and finished goods of ¥5.68bn, making demand forecasting, production scheduling and obsolescence control important. The annualized cash conversion cycle was 126 days, exceeding the 120-day warning threshold. The long cycle results from the combination of slow collection and high inventory holding periods, notwithstanding supplier financing through ¥6.62bn of electronically recorded obligations and ¥4.72bn of trade payables. For a manufacturer, this working-capital intensity is a material constraint on cash conversion and should be assessed against future revenue growth and margin recovery.

Dividend Sustainability

The full-year DPS forecast is ¥40.00, equal to an indicated dividend payout ratio of approximately 58.2% based on forecast EPS of ¥68.77. This is within the 60% sustainability benchmark, although it leaves a narrower earnings-retention buffer than a lower-payout policy. Q3 cumulative EPS was ¥62.23, so the forecast dividend is covered by reported year-to-date earnings. The company has a strong equity base of ¥43.77bn and substantial cash and deposits of ¥13.16bn, supporting financial flexibility for shareholder distributions. With full-year net income forecast at ¥1.40bn, the planned dividend appears aligned with forecast profitability. Sustained dividend capacity will nevertheless depend on preventing further gross-margin erosion and improving the long cash conversion cycle.

Risk Assessment

Business risks include Margin recovery risk: gross margin declined 88bp YoY and operating margin declined 163bp to 4.7%, indicating that sales growth is not currently converting into profit growth., Medical profitability risk: the core Medical business produced segment profit of ¥4.81bn, but this was down 7.4% YoY despite broadly stable sales., Tape business earnings risk: Tape sales grew 1.6% YoY, but segment profit declined 2.8% and the segment margin was only 3.1%, leaving earnings sensitive to input costs, pricing and volume changes., Manufacturing inventory risk: annualized DIO of 101 days exceeds the 90-day warning level, creating potential exposure to inventory obsolescence, demand misforecasting and production inefficiency., Foreign-exchange risk: FX gains of ¥0.03bn supported non-operating income; movements in exchange rates can affect overseas revenue translation and reported profit..

Financial risks include Collection risk: annualized DSO of 74 days exceeds the 60-day warning threshold, and trade receivables increased 14.0% YoY against 1.0% sales growth., Working-capital risk: the annualized cash conversion cycle of 126 days exceeds the 120-day warning level, tying more capital into receivables and inventories., Short-term maturity risk: current liabilities include ¥2.00bn of current portions of long-term loans, although the 217.5% current ratio and ¥21.80bn working-capital surplus provide strong coverage., Environmental and restoration obligation risk: total asset retirement obligations of ¥0.78bn equal about 3.2% of liabilities, requiring continued provision adequacy and compliance monitoring..

Key concerns include LOW_OPERATING_EFFICIENCY: EBIT margin of 4.7% is below 5%. The root cause is gross-margin pressure combined with SG&A growth of 4.0% exceeding revenue growth of 1.0%. This weakens operating leverage and constrains annualized ROE to 3.9%; restoring pricing, product mix or cost absorption is central to improving returns., HIGH_RECEIVABLE_DAYS: annualized DSO of 74 days is above 60 days. The elevated collection period is atypical versus the stated efficiency benchmark and coincides with receivables growth outpacing sales growth. The impact is greater cash tied up in customer balances and increased sensitivity to customer-payment delays., HIGH_INVENTORY_DAYS: annualized DIO of 101 days is above 90 days. The inventory burden is high for the stated manufacturing benchmark even though total inventories increased only modestly YoY. The impact is slower cash conversion and potential downside if demand weakens or product mix shifts., LONG_CCC: the annualized 126-day cash conversion cycle is above the 120-day warning level. It reflects the combined effect of slow receivable collection and high inventory days. The impact is reduced cash-generation efficiency and a higher need for disciplined working-capital management, even though near-term liquidity is strong..

Investment Implications

Key takeaways include Revenue growth of 1.0% was insufficient to protect earnings, with operating income down 25.1% and net income down 24.2%., The key profitability issue is negative operating leverage: gross margin declined 88bp while SG&A rose faster than sales., Medical is the core profit contributor, but its segment profit fell 7.4% YoY; Tape remains lower-margin despite better sales growth., Liquidity, capitalization and interest-service capacity remain strong, limiting balance-sheet stress., The annualized 126-day cash conversion cycle makes receivable and inventory discipline important determinants of earnings-to-cash conversion., Q3 progress exceeds the standard pace for profit forecasts, but the forecast itself embeds a lower full-year operating-profit level..

Metrics to watch include Gross margin and operating margin, particularly whether the 4.7% operating margin can recover above 5%., Medical segment sales and segment-profit margin., Tape segment margin and the profitability of industrial-products sales., Annualized DSO of 74 days, DIO of 101 days and the 126-day cash conversion cycle., Q4 operating income versus the ¥0.44bn implied requirement to meet the ¥2.20bn full-year forecast., Dividend payout ratio relative to the indicated 58.2% level..

Regarding relative positioning, Nichiban combines a conservative balance sheet and strong liquidity with below-benchmark profitability and elevated working-capital intensity. Its financial risk profile is comparatively resilient, but its operating profile is constrained by sub-5% EBIT margin, a low annualized ROE of 彩争霸json 3.9%, and weak conversion of modest sales growth into earnings.